Wednesday, February 26, 2025 | 3:00 – 4:00 PM CET (Central European Time)
With healthcare professionals (HCPs) demanding increasingly personalized and connected communication, pharma companies must transition from multichannel to omnichannel engagement methods. At the same time, they are under pressure to improve ROI with limited in-person meetings. But how can medical affairs teams make better use of digital channels to expand HCP access and deepen existing relationships?
Join us for our next webinar on "Connecting the Dots: Omnichannel Engagement in Rare Disease Medical Affairs" on February 26, 2025, at 3 PM CET. Together with Sarah Clark and Audrey Krassnitzer from Novo Nordisk, we will explore how to create impactful, tailored engagement strategies for medical affairs teams in the rare disease space.
What you'll learn:
- Introduction to the Omnichannel Approach: Discover why omnichannel strategies are essential for connecting with healthcare professionals and stakeholders in a meaningful way.
- Implementing the Omnichannel Model: Gain practical insights into building a strategy, overcoming challenges, and following best practices to enhance engagement.
- Case Studies and Key Learnings: Learn from real-world examples that showcase the impact and success of omnichannel strategies.
Don't miss this opportunity and register for free today!
Meet Our Speakers
Dragan Mileski (Host)
Co-Founder and CTO
Climedo
Dragan, an IT specialist driven by entrepreneurship, co-founded Climedo in 2017 with a mission to enhance medical treatment using intelligent software solutions. As the Chief Technology Officer (CTO), he leads teams dedicated to developing cutting-edge software aimed at transforming post-market Real-World Evidence (RWE) studies, providing real-time transparency of outcomes and fostering engagement with healthcare professionals.
Sarah Clark
Sr. Director, Medical Excellence & Ops
Novo Nordisk
Sarah is a high-energy and pragmatic leader with deep experience in launch and lifecycle management, rare disease and digital health. She has held various medical affairs roles at affiliate, regional and global levels and is currently the Global Head of Medical Excellence and Operations, Novo Nordisk Rare Disease.
Audrey Krassnitzer
Global MCE Director, Rare Disease
Novo Nordisk
Audrey has a brand: activator. She leads with an enthusiasm to achieve ambitious goals. Leading the Global Rare Disease Orchestrated Customer Engagement team at Novo Nordisk, she brings 15+ years of diverse experiences across commercial strategy, consulting and medical education agencies. Committed to advancing customer-centric innovation, Audrey partners to elevate the impact of Rare Disease initiatives.
What's on the Agenda?
-
Intro (Dragan Mileski)
-
Developing an Omnichannel Engagement Model for Rare Disease Medical Affairs (Sarah Clark and Audrey Krassnitzer)
-
Discussion and networking (all)
- Wrap-up (Dragan Mileski)
Your Takeaways
INSIGHTS
Gain valuable insights into meaningful omnichannel engagement strategies.
BEST PRACTICES
Discover real-world examples on the impact of solid omnichannel strategies.
NETWORKING & DISCUSSION
Talk to industry professionals and learn how they're tackling challenges similar to yours.
CLIMEDO
The leading European eCOA system for non-interventional studies, RWE and launch success
Climedo offers an all-in-one eCOA and EDC solution with hybrid capabilities for non-interventional studies and real-world evidence. By using a patient-centric approach and leveraging real-time data insights and visualizations around a study’s current progress, Climedo empowers its clients to better engage with healthcare professionals and other key opinion leaders (KOLs). This boosts awareness, stimulates scientific dialogue and accelerates the launch success of new medical innovations, thus reaching more patients faster.
Founded in Munich in 2017, Climedo is a leading trusted partner for pharma, MedTech, CROs and academia with over 1.7 million patients enrolled to date. Learn more at www.climedo.com.
